Kimelman & Baird LLC Decreases Stock Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Kimelman & Baird LLC lowered its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 44.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,012 shares of the company’s stock after selling 808 shares during the period. Kimelman & Baird LLC’s holdings in GE HealthCare Technologies were worth $79,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC purchased a new stake in GE HealthCare Technologies during the third quarter worth about $31,000. Continuum Advisory LLC boosted its holdings in GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after buying an additional 168 shares in the last quarter. Bank of Jackson Hole Trust purchased a new stake in GE HealthCare Technologies during the fourth quarter worth about $32,000. OFI Invest Asset Management purchased a new stake in GE HealthCare Technologies during the fourth quarter worth about $34,000. Finally, Avion Wealth boosted its holdings in GE HealthCare Technologies by 497.4% during the fourth quarter. Avion Wealth now owns 460 shares of the company’s stock worth $35,000 after buying an additional 383 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Performance

Shares of GEHC stock opened at $81.97 on Monday. GE HealthCare Technologies Inc. has a one year low of $74.51 and a one year high of $94.80. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. The company has a 50 day moving average price of $87.26 and a 200 day moving average price of $86.13. The firm has a market capitalization of $37.48 billion, a price-to-earnings ratio of 18.93, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The firm had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.33 billion. Sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on GEHC. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their price target for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. The Goldman Sachs Group raised shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and upped their price target for the company from $85.00 to $100.00 in a report on Tuesday, March 11th. Wells Fargo & Company upped their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Finally, Citigroup upped their price target on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, GE HealthCare Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $98.75.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.